Roche: to present new data to ASH
(CercleFinance.com) - Roche has announced that new data for its approved and investigational drugs will be presented at the 62nd fully virtual annual meeting of the American Society of Hematology (ASH) from 5-8 December 2020.
Eleven Roche drugs will be presented in more than 80 abstracts, including 22 oral presentations.
"With studies spanning 16 blood disorders, including non-Hodgkin lymphoma (NHL), leukaemia, multiple myeloma (MM) and haemophilia A, these data highlight the strength and breadth of Roche's haematology portfolio and pipeline, and commitment to developing innovative treatment solutions for patients in need," the group said.
Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development, said, "Our data reflect our ongoing commitment to following the science and improving the lives of patients with some of the most difficult-to-treat blood disorders".
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Eleven Roche drugs will be presented in more than 80 abstracts, including 22 oral presentations.
"With studies spanning 16 blood disorders, including non-Hodgkin lymphoma (NHL), leukaemia, multiple myeloma (MM) and haemophilia A, these data highlight the strength and breadth of Roche's haematology portfolio and pipeline, and commitment to developing innovative treatment solutions for patients in need," the group said.
Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development, said, "Our data reflect our ongoing commitment to following the science and improving the lives of patients with some of the most difficult-to-treat blood disorders".
Copyright (c) 2020 CercleFinance.com. All rights reserved.